REG - Abingdon Health PLC - c.US$2m multiplex diagnostic test contract win

Abingdon HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251110:nRSJ7469Ga&default-theme=true

RNS Number : 7469G  Abingdon Health PLC  10 November 2025

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the
publication of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public domain.

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

c.US$2m multiplex diagnostic test contract win

Development, scale-up and technical transfer for a semi-quantitative,
multiplex lateral flow test system

 

York, U.K.  10 November 2025: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and distributor of high quality and
effective rapid tests, announces a new contract win with an expected value of
approximately US$2 million.

 

The Company has signed a Master Service Agreement ("MSA") with a US-based
company for the development and scale up to manufacture of a
semi-quantitative, multiplex lateral flow test system. The MSA covers the
feasibility, optimisation, scale-up, and technical transfer to manufacturing
of the test for multiple analytes. The project is expected to take
approximately 24 months via works orders under the MSA which are expected to
total c. US$2 million. The project will be run from the Company's Madison,
Wisconsin facilities.

 

This contract win is another example of the strength of Abingdon Health's CDMO
offering which provides customers with comprehensive support to take an idea
through to commercial success. The expansion of the Company's Madison,
Wisconsin, USA manufacturing capabilities, which is being accelerated
following the recent £3.2m (net) fundraise and placing
(https://www.londonstockexchange.com/news-article/ABDX/result-of-placing-and-notice-of-gm/17277463)
, satisfies the increasing demand from USA-based customers requiring
development and manufacture. The Company is well placed to do this and has the
benefit of being supported by the Group's full CDMO and regulatory services
offering from York, UK.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
outlines the comprehensive support the Group provides to its international and
UK customers.

 

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "This
contract award demonstrates the value of our comprehensive CDMO platform, and
the benefit of our dual sites in USA and UK. It also illustrates the power and
flexibility of lateral flow testing. The ability to measure multiple analytes
semi-quantitatively, in a single test system, illustrates the utility of
lateral flow testing beyond the more widely known single parameter qualitative
'yes/no' devices.

 

"The expertise and experience of Abingdon scientists and the full end-to-end
CDMO service offering continues to resonate well with current and potential
clients."

 

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                            Via Walbrook PR
 Tom Hayes, CFO

 Zeus (Sole Broker and Nominated Adviser)                                    Tel: +44 (0)20 3829 5000
 Antonio Bossi / Jacob Walker (Corporate Finance)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format.  Abingdon Health
has the internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing, including companion diagnostics,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
and IVDeology, provide a broad range of regulatory services to the in vitro
diagnostic and wider medical device industry, to support customers in bringing
products to market across a range of territories including the USA, EU and the
UK.  Its consultancy services range from design, implementation and
maintenance of quality management systems, preparation of technical files for
regulatory approvals, part-time and interim management support, auditing both
internal and external, management reviews and presentations, training and
mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers
analytical testing and performance evaluation to generate the required
technical and data for regulatory approval for lateral flow and other in vitro
diagnostic assays from its Doncaster, England facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTQDLFBEFLZFBD



            Copyright 2019 Regulatory News Service, all rights reserved